Drug intelligence / Profile preview

BioStratum INSR program

Development stage: Preclinical
Lead developer: BioStratum

Overview

The BioStratum INSR program is a therapeutic development initiative focused on the treatment of diabetes mellitus through the modulation of the insulin receptor (INSR). Developed in collaboration with BioCrine AB, a spin-off from the Karolinska Institutet, the program aims to identify and develop agents that can activate or enhance the signaling pathways of the insulin receptor to improve glucose metabolism and insulin sensitivity. While the program was a key part of BioStratum's metabolic pipeline, specific details regarding lead candidates, chemical modalities, or clinical trial phases are limited due to the company's historical transition and the early-stage nature of the research assets.

Other names: Targeting InsR programBioCrine INSR program

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on BioStratum INSR program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioStratum INSR program.

Explore the full profile